Midodrin

Midodrin
(IUPAC) ime
	(RS)- N-[2-(2,5-dimetoksifenil)-2-hidroksietil]glicinamid
Klinički podaci
Robne marke	Proamatin
AHFS/Drugs.com	Monografija
MedlinePlus	a602023
Identifikatori
CAS broj	133163-28-7
ATC kod	C01CA17
PubChem	4195
DrugBank	DB00211
ChemSpider	4050
UNII	6YE7PBM15H
KEGG	D08220
ChEBI	CHEBI:6933
ChEMBL	CHEMBL1076
Hemijski podaci
Formula	C12H18N2O4
Mol. masa	254,282 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16) ; Key: PTKSEFOSCHHMPD-UHFFFAOYSA-N
Sinonimi	2-amino-N-[2-(2,5-dimetoksifenil)-2-hidroksi-etil]-acetamid
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Midodrin (Amatin, Proamatin, Gutron) je vazopresor/antihipotenzivni agens. Midodrin je odobren u Sjedinjenim Državama od strane FDA 1996 za lečenje disautonomije i ortostatičke hipotenzije.

Avgusta 2010, FDA je predložila povlačenje ovog proizvoda sa tržišta, je proizvođač Shire plc nije kompletirao mandatorne studije nakon početka prodaje leka.^[6]^[7] September 2010, FDA je odobrila da ostane dostupan dok se ne završe studije čiji cilj je prikupljanje podataka o efikasnosti i bezbednosti leka.^[8]^[9]

Stereokemija uredi

Midodrin sadrži stereocentar i sastoji se od dva enantiomera. Ovo je racemat, tj. Smjesa od 1: 1 ( R ) i ( S ) - oblik:^[10]

Enantiomeri midodrina
CAS-Nummer: 133163-25-4	CAS-Nummer: 133267-39-7

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ U.S. proposes withdrawal of Shire hypotension drug, Aug 16, 2010.
↑ O'Riordan, Michael. „FDA recommends withdrawal of midodrine”. Food and Drug Administration. FDA proposes withdrawal of low blood pressure drug [press release]. August 16, 2010.. TheHeart.org. Pristupljeno 1. 4. 2011. .
↑ Midodrine (ProAmatine, generic) Proposed Market Withdrawal – Update Arhivirano 2012-03-28 na Wayback Machine-u September 10, 2010.
↑ Shire Announces Update on ProAmatime September 27, 2011.
↑ Rote Liste Service GmbH (Hrsg.): Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, ISBN 978-3-946057-10-9, S. 196.

Vidi još uredi

Lisdeksamfetamin

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

Midodrine at drugs.com

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] U.S. proposes withdrawal of Shire hypotension drug, Aug 16, 2010.

[7] O'Riordan, Michael. „FDA recommends withdrawal of midodrine”. Food and Drug Administration. FDA proposes withdrawal of low blood pressure drug [press release]. August 16, 2010.. TheHeart.org. Pristupljeno 1. 4. 2011. .

[8] Midodrine (ProAmatine, generic) Proposed Market Withdrawal – Update Arhivirano 2012-03-28 na Wayback Machine-u September 10, 2010.

[9] Shire Announces Update on ProAmatime September 27, 2011.

[Rote_Liste-10] Rote Liste Service GmbH (Hrsg.): Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, ISBN 978-3-946057-10-9, S. 196.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]